
Research findings scheduled to be presented at the CHEST meeting show broad positive cardiopulmonary effects from GLP-1s and an association with a reduced risk of acute respiratory failure.
Current estimates indicate that overactive bladder is a widespread disorder. Yet, these figures only capture people willing to admit to symptoms.






